Shinil Pharmaceutical sells medicines in Korea and overseas, built on plaster and patch manufacturing know-how, and runs contract manufacturing for other pharmaceutical companies alongside. Its contract manufacturing work is described as covering products for about 80 companies.
By business segment, pharmaceuticals made up 96% of Q2 2026 revenue, cosmetics 2%, real estate 1%, and quasi-drugs 1%.
A product-level breakdown dated March 2026 puts general and prescription drugs, veterinary drugs and OEM work in an 'other' group at 72%, with Defenplasta at 9%, Harupenplasta at 7%, Lipicanjeong at 3%, and other items at 8%.
The two classifications differ and cannot be compared directly, but pharmaceuticals dominate under either view. New ventures include the Pharmtree functional cosmetics brand, with health functional foods, veterinary drugs and quasi-drugs also under way.
A 2024 first-half report put cosmetics and health functional foods together at 3.1% of revenue. In earlier reporting, the company said it planned to expand prescription drug sales and consider a larger CSO network. The largest shareholder group, led by Hong Jae-hyun with 22 others, holds 32.67%.